Download PDF
Aktuelle Urol 2003; 34(7): 458-468
DOI: 10.1055/s-2003-45263
Übersichtsarbeit
© Georg Thieme Verlag Stuttgart · New York

Grundlagen der Antisense-Oligonukleotid-Therapie und derzeitige Therapiestrategien in der Urologie

Basics of Antisense Oligonucleotide Therapy and Current Therapeutical Strategies in UrologyI.  Kausch1 , A.  Böhle1
  • 1Klinik für Urologie, Med. Universität Lübeck und Laborgruppe Immuntherapie, Forschungszentrum Borstel
Further Information

Publication History

Publication Date:
04 December 2003 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Antisense-Oligonukleotide sind kurzsträngige DNA-Sequenzen, durch die der Informationstransfer vom Gen zum Protein moduliert werden kann. Sie besitzen die umgekehrte, komplementäre Nukleotidabfolge der gewünschten Zielsequenz. Durch Hybridisierung mit der messenger-RNA (mRNA) eines spezifischen Proteins wird eine selektive Hemmung der Genexpression und Herunterregulation des Proteins induziert. Die Antisense-Technik ermöglicht so eine Therapie bereits auf molekularer Ebene und überdies die Untersuchung der Funktion einzelner Gene. Prinzipiell kann die Expression jedes Proteins inhibiert werden. In dieser Übersichtsarbeit werden die molekularen Grundlagen der Antisense-Therapie erörtert und die bisherigen urologischen Studien umfassend dargestellt. Präklinische Studien haben gezeigt, dass die Antisense-Technik ein viel versprechendes Konzept in der Onkologie darstellt. In derzeit laufenden klinischen Studien wird die Effektivität von Antisense-Oligonukleotiden gegen verschiedene unterschiedliche krebsassoziierte Gene untersucht. Obwohl in einigen dieser Studien auch urologische Patienten z. B. mit fortgeschrittenem Prostatakarzinom eingebracht wurden, befindet sich die Antisense-Therapie in der Urologie noch in den Anfängen.

Abstract

Antisense oligonucleotides are short DNA sequences designed to modulate the information transfer from gene to protein. Sequence-related hybridisation with the mRNA of a specific protein results in selective inhibition of gene expression and downregulation of protein expression. This allows the study of gene function and therapy on a molecular level. Antisense oligonucleotide inhibitors can be designed directly from genomic sequence information by simply making the reversed complement of the desired sequence. In this review, we focus on the mechanisms of action of antisense oligonucleotides and summarize the progress in urological antisense therapy. The ability to inhibit individual gene expression with antisense oligonucleotides has been promising in preclinical cancer models. Current clinical studies test antisense compounds targeted against various cancer related genes. Although some of these studies comprise patients with urological tumors, such as advanced prostate cancer, experimental antisense therapy in urology is still in its infancy.

Schlüsselwörter

Übersicht - Urologie - Antisense - Antisense-Oligonukleotide - Antisense-Strategie

Key words

Review - urology - antisense - antisense oligonucleotides - antisense strategy

Literatur

  • 1 Zamecnik P C, Stephenson M L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.  Proc Natl Acad Sci. 1978;  75 280-284
    CrossrefPubMedGoogle Scholar
  • 2 Marwick C. First “antisense” drug will treat CMV retinitis.  JAMA. 1998;  280 871
    CrossrefPubMedGoogle Scholar
  • 3 Herschlag D. Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better.  Proc Natl Acad Sci. 1991;  88 6921-6925
    PubMedGoogle Scholar
  • 4 Shaw J P, Kent K, Bird J, Fishback J, Froehler B. Modified deoxyoligonucleotides stable to exonuclease degradation in serum.  Nucl Acids Res. 1991;  19 747-750
    PubMedGoogle Scholar
  • 5 Neckers L M. Cellular internalization of oligodeoxynucleotides. In: Crooke ST, Lebleu B. Antisense Research and Applications Los Angeles, USA: CRC Press 1993 451: 451-460
    Google Scholar
  • 6 Agrawal S, Temsamani J, Tang J Y. Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.  Proc Natl Acad Sci USA. 1991;  88 7595-7599
    CrossrefPubMedGoogle Scholar
  • 7 Schlingensiepen R, Brysch W, Schlingensiepen K H. Antisense - from technology to therapy. Lab manual and textbook. Williston, USA: Blackwell Science 1996 Vol. 6
    Google Scholar
  • 8 Levin A A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.  Biochim Biophys Acta. 1999;  1489 69-84
    PubMedGoogle Scholar
  • 9 Crooke R M, Graham M J, Cooke M E, Crooke S T. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides.  J Pharmacol Exp Ther. 1995;  275 462-473
    PubMedGoogle Scholar
  • 10 Krieg A M, Tonkinson J, Matson S, Zhao Q, Saxon M, Zhang L M, Yakubov L, Stein C A. Modification of antisense phosphodiester oligodeoxynucleotides by a 5′ cholesteryl moiety increases cellular association and improves efficacy.  Proc Natl Acad Sci. 1993;  90 1048-1052
    PubMedGoogle Scholar
  • 11 Tondelli L, Ricca A, Laus M, Lelli M, Citro G. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres.  Nucl Acids Res. 1998;  26 5425-5431
    CrossrefPubMedGoogle Scholar
  • 12 Citro G, Perrotti D, Cucco C, D'Agnano I, Sacchi A, Zupi G, Calabretta B. Inhibition of leukemia cell proliferation by receptor-mediated uptake of c-myb antisense oligodeoxynucleotides.  Proc Nat Acad Sci. 1992;  89 7031-7035
    PubMedGoogle Scholar
  • 13 Wu G Y, Wu C H. Specific inhibition of hepatitis B viral gene expression in vitro by targeted antisense oligonucleotides.  J Biol Chem. 1992;  267 12 436-12 439
    PubMedGoogle Scholar
  • 14 Stein C A. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments.  Biochim Biophys Acta. 1999;  1489 45-52
    PubMedGoogle Scholar
  • 15 Jaaskelainen I, Monkkonen J, Urtti A. Oligonucleotide-cationic liposome interactions. A physicochemical study.  Biochim Biophys Acta. 1994;  1195 115-123
    PubMedGoogle Scholar
  • 16 Bennett C F, Chiang M Y, Chan H, Shoemaker J E, Mirabelli C K. Cationic lipids enhance cellular uptake and activity of phosphorothiotae antisense oligonucleotides.  Mol Pharmacol. 1992;  41 1023-1033
    PubMedGoogle Scholar
  • 17 Mirabelli C K, Bennett C F, Anderson K, Crooke S T. In vitro and in vivo pharmacologic activities of antisense oligonucleotides.  Anticancer Drug Des. 1991;  6 647-661
    PubMedGoogle Scholar
  • 18 Kitajima I, Shinohara T, Bilakovics J, Brown D A, Xu X, Nerenberg M. Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B (letter).  Science. 1993;  259 1523
    PubMedGoogle Scholar
  • 19 Crooke S T. Molecular mechanisms of action of antisense drugs.  Biochim Biophys Acta. 1999;  1489 31-44
    PubMedGoogle Scholar
  • 20 Baker B F, Miraglia L, Hagedorn C H. Modulation of eucaryotic initiation factor-4E binding to 5′-capped oligoribonucleotides by modified anti-sense oligonucleotides.  J Biol Chem. 1992;  267 11 495-11 499
    PubMedGoogle Scholar
  • 21 Sierakowska H, Sambade M J, Agrawal S, Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.  Proc Natl Acad Sci. 1996;  93 12 840-12 844
    PubMedGoogle Scholar
  • 22 Krieg A M, Yi A K, Matson S, Waldschmidt T J, Bishop G A, Teasdale R, Koretzky G A, Klinman D M. CpG motifs in bacterial DNA trigger direct B-cell activation.  Nature. 1995;  374 546-549
    CrossrefPubMedGoogle Scholar
  • 23 Klinman D M. Therapeutic applications of CpG-containing oligodeoxynucleotides.  Antisense nucleic acid drug dev. 1998;  8 181-184
    PubMedGoogle Scholar
  • 24 Yamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length.  Antisense Res Dev. 1994;  4 119-122
    PubMedGoogle Scholar
  • 25 Moldoveanu Z, Love-Homan L, Huang W Q, Krieg A M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus.  Vaccine. 1998;  16 1216-1224
    CrossrefPubMedGoogle Scholar
  • 26 Wooldridge J E, Ballas Z, Krieg A M, Weiner G J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma.  Blood. 1997;  89 2994-2998
    PubMedGoogle Scholar
  • 27 Ramanathan M, Lantz M, MacGregor R D, Garavoy M R, Hunt C A. Characterization of the oligodeoxynucleotide-mediated inhibition of interferon-gamma-induced major histocompatibility complex class I and intercellular adhesion molecule-1.  J Biol Chem. 1994;  269 24 564-24 574
    PubMedGoogle Scholar
  • 28 Yaswen P, Stampfer M R, Ghosh K, Cohen J S. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells.  Antisense Res Dev. 1993;  3 67-77
    PubMedGoogle Scholar
  • 29 Agrawal S, Zhao Q. Antisense therapeutics.  Curr Opin Chem Biol. 1998;  2 519-528
    CrossrefPubMedGoogle Scholar
  • 30 Sereni D, Tubiana R, Lascoux C, Katlama C, Taulera O, Bourque A, Dvorchik B, Martin R R. Pharmacokinetics and tolerability of intravenous trecovirsen (GEM 91), an antisense phosphorothioate oligonucleotide, in HIV-positive subjects.  J Clin Pharmacol. 1999;  39 47-54
    CrossrefPubMedGoogle Scholar
  • 31 Cotter F E. Antisense therapy of hematologic malignancies.  Semin Hematol. 1999;  36 9-14
    PubMedGoogle Scholar
  • 32 Yuen A R, Halsey J, Fisher G A, Holmlund J T, Geary R S, Kwoh T J, Dorr A, Sikic B I. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP 64128A) in patients with cancer.  Clin Cancer Res. 1999;  5 3357-3363
    PubMedGoogle Scholar
  • 33 Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G. A theoretical approach to select effective antisense oligodeoxyribonucleotides at high statistical probability.  Nucl Acids Res. 1999;  27 4328-4334
    CrossrefPubMedGoogle Scholar
  • 34 Ho S P, Bao Y, Lesher T, Malhotra R, Ma L Y, Fluharty S J, Sakai R R. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries.  Nat Biotechnol. 1998;  16 59-63
    PubMedGoogle Scholar
  • 35 Jain R K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies.  J Natl Cancer Inst. 1989;  81 570-576
    CrossrefPubMedGoogle Scholar
  • 36 Plenat F N, Klein-Monhoven B M, Vignaud J M, Duprez A. Cell and tissue distribution of synthetic oligonucleotides in healthy and tumorbearing mice.  Am J Path. 1995;  147 124-135
    PubMedGoogle Scholar
  • 37 Nishida E, Gotho Y. The MAP kinase cascade is essential for diverse signal transduction pathways.  Trends Biochem Sci. 1993;  18 128-131
    CrossrefPubMedGoogle Scholar
  • 38 Daum G, Eisenmann-Tappe I, Fries H W, Troppmair J, Rapp U R. The ins and outs of RAF kinases.  Trends Biochem Sci. 1994;  19 474-480
    CrossrefPubMedGoogle Scholar
  • 39 Cho-Chung Y S. Antisense oligonucleotide inhibition of serine/threonine kinases: an innovative approach to cancer treatment.  Pharmacol Ther. 1999;  82 437-449
    CrossrefPubMedGoogle Scholar
  • 40 Bos J L. ras oncogenes in human cancer: a review.  Cancer Res. 1989;  49 4682-4699
    PubMedGoogle Scholar
  • 41 Adjei A A. Blocking oncogenic Ras signaling for cancer therapy.  J Natl Cancer Inst. 2001;  93 1062-1074
    CrossrefPubMedGoogle Scholar
  • 42 Brown D, Yu Z P, Miller P. et al . Modulation of ras expression by antisense, nonionic deoxyoligonucleotide analogs.  Oncogene Res. 1989;  4 243-252
    PubMedGoogle Scholar
  • 43 Saison-Behmoaras T, Tocque B, Rey I. et al . Short modified antisense oligonucleotides directed against Ha-ras point mutation induce selective cleavage of the mRNA and inhibit T24 cells proliferation.  EMBO. 1991;  10 1111-1118
    PubMedGoogle Scholar
  • 44 Gray G D, Hernandez O M, Hebel D, Root M, Pow-Sang J M, Wickstrom E. Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice.  Cancer Res. 1993;  53 577-580
    PubMedGoogle Scholar
  • 45 Gordon M S, Sandler A B, Holmlund J T, Dorr A, Battiato L, Fife K, Geary R, Kwoh T J. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, administered by a 24-hour weekly infusion to patients with advanced cancer. Proc Am Soc Clin Oncol 1999 157 abstract
    Google Scholar
  • 46 Dorr A, Bruce J, Monia B, Johnston J, Geary R, Kwoh T J, Holmlund J T, Nemunaitis J. Phase I and pharmacokinetic trial of ISIS 2503, a 20-mer antisense oligonucleotide against H-ras, by 14-day continuous infusion in patients with advanced cancer. Proc Am Soc Clin Oncol 1999 157, abstract
    Google Scholar
  • 47 Marais R, Light Y, Paterson H F, Mason C S, Mashall C J. Differential regulation of Raf-1, A-Raf and B-Raf by oncogenic ras and tyrosine kinases.  J Biol Chem. 1997;  272 4378-4383
    CrossrefPubMedGoogle Scholar
  • 48 Wang H G, Rapp U R, Reed J C. Bcl-2 targets the protein kinase RAF-1 to mitochondria.  Cell. 1996;  87 629-638
    CrossrefPubMedGoogle Scholar
  • 49 Shimizu K, Nakatsu Y, Sekiguchi M, Hokamura K, Tanaka K, Terada M, Sugimura T. Molecular cloning of an activated human oncogene, homologous to v-raf, from primary stomach cancer.  Proc Natl Acad Sci. 1985;  82 5641-5645
    PubMedGoogle Scholar
  • 50 Fukui M, Yamamoto T, Kawai S, Maruo K, Toyoshima K. Detection of a raf-related and two other transforming DNA sequences in human tumors maintained in nude mice.  Proc Natl Acad Sci. 1985;  82 5954-5958
    PubMedGoogle Scholar
  • 51 Monia B P, Johnston J F, Geiger T, Müller M, Fabro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.  Nature Med. 1996;  2 668-675
    PubMedGoogle Scholar
  • 52 Monia B P. Anti-tumor activity of C-raf antisense-correction.  Nat Med. 1999;  5 127
    PubMedGoogle Scholar
  • 53 Lau Q C, Brusselbach S, Muller R. Abrogation of c-Raf expression induces apoptosis in tumor cells.  Oncogene. 1998;  16 (14) 1899-1902
    CrossrefPubMedGoogle Scholar
  • 54 Geiger T, Muller M, Monia B P, Fabbro D. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.  Clin Cancer Res. 1997;  3 1179-1185
    PubMedGoogle Scholar
  • 55 Stevenson J P, Yao K S, Gallagher M, Friedland D, Mitchell E P, Cassella A, Monia B, Kwoh T J. Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP69846A).  J Clin Oncol. 1999;  17 2227-2236
    PubMedGoogle Scholar
  • 56 Cunningham C C, Holmlund J T, Schiller J H, Geary R S, Kwoh T J, Dorr A, Nemunaitis J. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.  Clin Cancer Res. 2000;  6 1607-1610
    PubMedGoogle Scholar
  • 57 Rudin C M, Holmlund J, Fleming G F, Mani S, Stadler W M, Schumm P, Monia B P, Johnston J F. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.  Clin Cancer Res. 2001;  7 1214-1220
    PubMedGoogle Scholar
  • 58 Grandori C, Cowley S M, James L P, Eisenman R N. The Myc/Max/Mad network and the transcriptional control of cell behaviour.  Annu Rev Cell Dev Biol. 2000;  16 653-699
    CrossrefPubMedGoogle Scholar
  • 59 DePinho R A, Schreiber-Agus N, Alt F W. myc family oncogenes in the development of normal and neoplastic cells.  Adv Cancer Res. 1991;  57 1-46
    PubMedGoogle Scholar
  • 60 Nesbit C E, Tersak J M, Prochownik E V. Myc oncogenes and human neoplastic disease.  Oncogene. 1999;  18 3004-3016
    CrossrefPubMedGoogle Scholar
  • 61 Balaji K C, Koul H, Mitra S, Maramag C, Reddy P, Menon M, Malhotra R K, Laxmanan S. Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer.  Urology. 1997;  50 1007-1015
    CrossrefPubMedGoogle Scholar
  • 62 Mizutani Y, Bonavida B, Fukumoto M, Yoshida O. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.  J Immunother Emphasis Tumor Immunol. 1995;  17 78-87
    PubMedGoogle Scholar
  • 63 Langzam L, Koren R, Gal R, Kugel V, Paz A, Farkas A, Sampson S R. Patterns of protein kinase C isoenzyme expression in transitional cell carcinoma of bladder. Relation to degree of malignancy.  Am J Clin Pathol. 2001;  116 377-385
    CrossrefPubMedGoogle Scholar
  • 64 Yuspa S H. The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogensis-thirty-third G. H. A. Clowes Memorial Award Lecture.  Cancer Res. 1994;  54 1178-1189
    PubMedGoogle Scholar
  • 65 Dean N, McKay R, Miraglia L, Howard R, Cooper S, Giddings J, Nicklin P, Meister L. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of protein kinase C-α expression.  Cancer Res. 1996;  56 3499-3507
    PubMedGoogle Scholar
  • 66 Mani S, Rudin C M, Kunkel K, Holmlund J T, Geary R S, Kindler H L, Dorr F A, Ratain M J. Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.  Clin Cancer Res. 2002;  8 1042-1048
    PubMedGoogle Scholar
  • 67 Villalona-Carlero M A, Figueroa J, Nadella P, Otterson G A, Snider P, Browning K, D'Amato N P, Geary R S. Phase I and pharmacokinetic (PK) study of the protein kinase C alpha (PKC-a) inhibitor ISIS-3521 in combination with cisplatin and gemcitabine in patients with solid malignancies. Florida: AACR-NCI-EORTC International Conference Miami Beach 2001, abstract
    Google Scholar
  • 68 Yuen A, Halsey J, Fisher G, Advani R, Moore M, Saleh M, Ritch P, Harker G. Phase II trial of ISIS 3521, an antisense inhibitor of PKC-a, with carboplatin and paclitaxel in non-small cell lung cancer: Update survival and time to progression data. Florida: AACR-NCI-EORTC International Conference Miami Beach 2001, abstract
    Google Scholar
  • 69 Gordge P C, Hulme M J, Clegg R A, Miller W R. Elevation of protein kinase A and protein kinase C activities in malignant as compared with normal human breast tissue.  Eur J Cancer. 1996;  32A 2120-2126
    PubMedGoogle Scholar
  • 70 Cho-Chung Y S. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy.  Cancer Res. 1990;  50 7093-7100
    PubMedGoogle Scholar
  • 71 Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.  Proc Nat Acad Sci. 1999;  96 13 989-13 994
    PubMedGoogle Scholar
  • 72 Chen H X, Marshall J L, Ness E, Martin R R, Dvorchik B, Rizvi N, Marquis J, McKinlay M. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.  Clin Cancer Res. 2000;  6 1259-1266
    PubMedGoogle Scholar
  • 73 Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco A R, Agrawal S. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.  J Natl Cancer Inst. 1998;  90 1087-1094
    CrossrefPubMedGoogle Scholar
  • 74 Chao D T, Korsmeyer S J. BCL-2 family: regulators of cell death.  Annu Rev Immunol. 1998;  16 395-419
    CrossrefPubMedGoogle Scholar
  • 75 Green D R, Reed J C. Mitochondria and apoptosis.  Science. 1998;  281 1309-1312
    CrossrefPubMedGoogle Scholar
  • 76 Gautschi O, Tschopp S, Olie R A, Leech S H, Simoes-Wust A P, Ziegler A, Baumann B, Odermatt B. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.  J Natl Cancer Inst. 2001;  93 463-471
    CrossrefPubMedGoogle Scholar
  • 77 Miyake H, Tolcher A, Gleave M E. Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.  Cancer Res. 1999;  59 4030-4034
    PubMedGoogle Scholar
  • 78 Miayake H, Tolcher A, Gleave M E. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.  J Natl Cancer Inst. 2000;  92 34-41
    CrossrefPubMedGoogle Scholar
  • 79 Tolcher A W, Roth S, Wynne H, Quada J, Rowinsky E K, Thompson I M, Weitmann S, Izbicka E. G3139 (Genasense™) enhances docetaxel antitumor activity and leads to long-term survivors in the androgen-independent prostate cancer xenograph (PC3) model. Florida: AACR-NCI-EORTC International Conference Miami Beach 2001, abstract
    Google Scholar
  • 80 Dorai T, Olsson C A, Katz A E, Buttyan R. Development of a hammerhead ribozyme against bcl-2.1. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.  Prostate. 1997;  32 246-258
    CrossrefPubMedGoogle Scholar
  • 81 Uchida T, Gao J-P, Sato T, Irie A, Iwamura M, Baba S. Antisense BCL-2 oligodeoxynucleotides enveloped in Lipofectin induces growth inhibition in human renal cell carcinoma in vitro and in nude mice. AUA Annual Meeting 2000 abstract
    Google Scholar
  • 82 Waters J, Webb A, Cunningham D, Clarke P A, di Stefano F, Raynaud B DB, Cotter F E. Results of a phase I clinical trial of bcl-2 antisense molecule G3139 (GENTA) in patients with non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1999 4, abstract
    Google Scholar
  • 83 Morris M, Tong W, Osman I, Maslak P, Kelly W K, Terry K, Rosen N, Scher H I. A phase I/II dose-escalating trial of bcl-2 antisense (G3139) treatment by 14-day continuous intravenous infusion for patiens with androgen-independent prostate cancer or other advanced solid tumor malignancies. Proc Am Soc Clin Oncol 1999 323, abstract
    Google Scholar
  • 84 Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hollenstein U, Lucas T, Eichler H-G, Wolff K. A phase I-II study with dacarbazine and bcl-2 antisense oligonucleotide G3139 (GENTA) as a chemosensitizer in patients with advanced malignant melanoma. Proc Am Soc Clin Oncol 1999 531, abstract
    Google Scholar
  • 85 Marcucci G, Byrd J C, Cataland S R, Fisher D B, Lucas D, Chen K K, Young D, Didier L A. Significant disease response to Genasense™ (Genta Inc) (GS), a bcl-2 antisense, in combination with chemotherapy in refractory (REF) or relapsed (REL) acute leukemia (AL). Florida: AACR-NCI-EORTC International Conference Miami Beach 2001
    Google Scholar
  • 86 Duggan B, Tschopp S, Zangemeister-Wittke U, Williamson K, Keane P, Johnston S R. BCL-2 and BCL-XL antisense as a gene therapy strategy in bladder cancer. Eur Urol 2001 39 (S5): 172, abstract
    Google Scholar
  • 87 Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy.  J Immunother. 1997;  20 165-177
    PubMedGoogle Scholar
  • 88 Inge T H, Hoover S K, Susskind B M, Barrett S K, Bear H D. Inhibition of tumor-specific cytotoxic T-Lymphocyte responses by transforming growth factor β1.  Cancer Res. 1992;  52 1386
    PubMedGoogle Scholar
  • 89 Torre-Amione G, Beauchamp R DA, Koeppen H, Park B H, Schreiber H, Moses H L, Rowley D A. A highly immunogenic tumor transfected with murine transforming growth factor type β1 cDNA escapes immune surveillance.  Proc Natl Acad Sci USA. 1990;  87 1486-1490
    PubMedGoogle Scholar
  • 90 Tzai T-S, Lin C I, Shiau A L, Wu C L. Antisense oligonucleotide specific for transforming growth factor-beta1 inhibit both in vitro and in vivo growth of MBT-2 murine bladder cancer.  Anticancer Res. 1998;  18 1585-1590
    PubMedGoogle Scholar
  • 91 Kausch I, Lingnau A, Deinert I, Endl E, Jocham D, Gerdes J, Böhle A. Antisense therapy against the KI-67 MRNA - A new antitumoral approach. Eur Urol 2001 39 (suppl 5): 172, abstract
    Google Scholar
  • 92 Achenbach T V, Muller R, Slater E P. Synergistic antitumor effect of chemotherapy and antisense-mediated ablation of the cell cycle inhibitor p27KIP-1.  Clin Cancer Res. 2000;  6 3006-3014
    PubMedGoogle Scholar
  • 93 Wang H, Nan L, Shi Z, Agrawal S, Zhang R. Modulation of gene expression and inhibition of tumor growth by antisense anti-MDM2 oligonucleotides in prostate cancer. Florida: AACR-NCI-EORTC International Conference Miami Beach 2001
    Google Scholar
  • 94 Gnarra J R, Dressler G R. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides.  Cancer Res. 1995;  55 4092-4098
    PubMedGoogle Scholar
  • 95 Kiyama S, Zellweger T, Miyake H, Gleave M. Antisense insulin-like growth factor binding protein-2 oligonucleotides induce apoptosis and delay progression to androgen-independence after castration in human prostae cancer tumor models. Eur Urol 2001 39 (S5): 94, abstract
    Google Scholar
  • 96 Eder I E, Culig Z, Ramoner R, Thurnher M, Putz T, Nessler-Menardi C, Tiefenthaler M, Bartsch G. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.  Cancer Gene Ther. 2000;  7 997-1007
    CrossrefPubMedGoogle Scholar

Prof. Dr. med. A. Böhle

Klinik für Urologie · Medizinische Universität zu Lübeck

Ratzeburger Allee 160

23538 Lübeck

Phone: 0451-500-6112

Fax: 0451-500-6112

Email: boehle@medinf.mu-luebeck.de

      >